亚虹医药成立于2010年3月，是一家专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化创新药公司。 秉承“改善人类健康，让生命更有尊严”的企业使命，亚虹立志成为在专注治疗领域集研发、生产和商业化为一体的国际领先制药企业，为中国和全球患者提供最佳的诊疗一体化解决方案。
Total raised: $106M
Founded date: 2010
Investors 3
| Date | Name | Website |
| - | triwise | en.triwise... |
| - | Qiming Ven... | qimingvent... |
| 21.11.2020 | Qiming Ven... | qimingvc.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.11.2020 | - | $106M | Qiming Ven... |
Mentions in press and media 4
| Date | Title | Description |
| 04.08.2026 | Photocure ASA: Asieris counterclaim on milestone payment arbitration | Photocure ASA: Asieris counterclaim on milestone payment arbitration Tue, Aug 04, 2026 08:00 CET Report this content Oslo, Norway, August 4, 2026 – Reference is made to Photocure ASA's (OSE: PHO) announcement dated 3 March 2026, in which Ph... |
| 18.05.2023 | Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer | SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related dis... |
| 11.11.2020 | China’s Asieris Pharmaceuticals bags over $106m funding led by Qiming | Premium Genitourinary tumour therapy developer Asieris Pharmaceuticals has closed a Series D round of financing raising over 700 million yuan ($106 million) led by Chinese global venture capital firm Qiming Venture Partners, according to a ... |
| 11.11.2020 | China’s Asieris Pharmaceuticals bags over $106m funding led by Qiming | Genitourinary tumour therapy developer Asieris Pharmaceuticals has closed a Series D round of financing raising over 700 million yuan ($106 million) led by Chinese global venture capital firm Qiming Venture Partners, according to a company ... |